UBS Reiterates Neutral Rating on Exact Sciences (EXAS) Following Abbott Deal Reports
Tweet Send to a Friend
UBS analyst Dan Leonard reiterated a Neutral rating and $80.00 price target on Exact Sciences (NASDAQ: EXAS).The analyst commented, "Bloomberg ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
